



23 August 2018
EMA/570147/2018
Inspections, Human Medicines Pharmacovigilance & Committees Division

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Homogenate of antlerogenic stem cells.

Brief description of the finished product

Biocervin Neuroprotective matrix containing homogenate of antlerogenic stem cells and medical collagen type I.

Proposed indication

Therapeutic support in spinal cord injury.

EMA/CAT conclusion

The procedure was finalised on 20 July 2018 for the following recommendation.

On the basis that:

- the product consists of non-viable cells of animal origin;



- the cells have been subjected to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration or repair are achieved,

the EMA/CAT considers that the product falls within the definition of a tissue engineered product, as provided in Article 2(4) of Regulation (EC) 1394/2007.